Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference

Marta Rodríguez-Arias; Carmen Manzanedo; Concepción Roger-Sánchez; Bruno Ribeiro Do Couto; María Asunción Aguilar; José Miñarro

doi:10.1016/j.pnpbp.2009.10.019

Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):166-71. doi: 10.1016/j.pnpbp.2009.10.019. Epub 2009 Oct 30.

Authors

Marta Rodríguez-Arias¹, Carmen Manzanedo, Concepción Roger-Sánchez, Bruno Ribeiro Do Couto, María Asunción Aguilar, José Miñarro

Affiliation

¹ Facultad de Psicología, Departamento de Psicobiología, Unidad de Investigación Psicobiología de las Drogodependencias, Universitat de Valencia, Avda. Blasco Ibáñez 21, 46010 Valencia, Spain.

PMID: 19883712
DOI: 10.1016/j.pnpbp.2009.10.019

Abstract

The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Analysis of Variance
Animals
Animals, Newborn
Benzoxazines / administration & dosage*
Calcium Channel Blockers / administration & dosage*
Cannabinoid Receptor Antagonists
Conditioning, Operant / drug effects*
Dose-Response Relationship, Drug
Drug Interactions
Extinction, Psychological / drug effects
Hallucinogens / pharmacology
Male
Mice
Morpholines / administration & dosage*
N-Methyl-3,4-methylenedioxyamphetamine / pharmacology
Naphthalenes / administration & dosage*
Piperidines / pharmacology
Pyrazoles / pharmacology
Reinforcement Schedule
Rimonabant
Spatial Behavior / drug effects*
Time Factors

Substances

Benzoxazines
Calcium Channel Blockers
Cannabinoid Receptor Antagonists
Hallucinogens
Morpholines
Naphthalenes
Piperidines
Pyrazoles
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
N-Methyl-3,4-methylenedioxyamphetamine
Rimonabant